Your browser doesn't support javascript.
loading
Azilsartan ameliorates ventricular hypertrophy in rats suffering from pressure overload-induced cardiac hypertrophy by activating the Keap1-Nrf2 signalling pathway.
Hou, Ning; Li, Li-Rong; Shi, Yong-Ying; Yuan, Wen-Chang; Zhao, Gan-Jian; Liu, Xia-Wen; Cai, Shao-Ai; Huang, Yin; Zhan, Hao-Xin; Pan, Wei-Biao; Luo, Cheng-Feng.
Afiliação
  • Hou N; Guangzhou Institute of Cardiovascular Disease, Guangdong Key Laboratory of Vascular Diseases, State Key Laboratory of Respiratory Disease, The Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, China.
  • Li LR; Key Laboratory of Molecular Target and Clinical Pharmacology, School of Pharmaceutical Sciences and the Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou, China.
  • Shi YY; Guangzhou Institute of Cardiovascular Disease, Guangdong Key Laboratory of Vascular Diseases, State Key Laboratory of Respiratory Disease, The Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, China.
  • Yuan WC; Tungwah Hospital of Sun Yat-sen University, Dongguan, China.
  • Zhao GJ; Department of Geriatrics, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, China.
  • Liu XW; Key Laboratory of Molecular Target and Clinical Pharmacology, School of Pharmaceutical Sciences and the Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou, China.
  • Cai SA; Department of Clinical Laboratory, General Hospital of Xinjiang Military Region, Urumqi, China.
  • Huang Y; Guangzhou Institute of Cardiovascular Disease, Guangdong Key Laboratory of Vascular Diseases, State Key Laboratory of Respiratory Disease, The Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, China.
  • Zhan HX; Guangzhou Institute of Cardiovascular Disease, Guangdong Key Laboratory of Vascular Diseases, State Key Laboratory of Respiratory Disease, The Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, China.
  • Pan WB; Key Laboratory of Molecular Target and Clinical Pharmacology, School of Pharmaceutical Sciences and the Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou, China.
  • Luo CF; Guangzhou Institute of Cardiovascular Disease, Guangdong Key Laboratory of Vascular Diseases, State Key Laboratory of Respiratory Disease, The Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, China.
J Pharm Pharmacol ; 73(12): 1715-1725, 2021 Dec 07.
Article em En | MEDLINE | ID: mdl-34343333
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Oxidiazóis / Benzimidazóis / Cardiomegalia / Estresse Oxidativo / Fator 2 Relacionado a NF-E2 / Antagonistas de Receptores de Angiotensina / Proteína 1 Associada a ECH Semelhante a Kelch / Miocárdio Limite: Animals Idioma: En Revista: J Pharm Pharmacol Ano de publicação: 2021 Tipo de documento: Article País de afiliação: China País de publicação: Reino Unido
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Oxidiazóis / Benzimidazóis / Cardiomegalia / Estresse Oxidativo / Fator 2 Relacionado a NF-E2 / Antagonistas de Receptores de Angiotensina / Proteína 1 Associada a ECH Semelhante a Kelch / Miocárdio Limite: Animals Idioma: En Revista: J Pharm Pharmacol Ano de publicação: 2021 Tipo de documento: Article País de afiliação: China País de publicação: Reino Unido